ANGLE plc (ANPCF)
USD 0.16
(0.0%)
USD 0.16
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.24 Million GBP | -15.92% |
| 2022 | 9.8 Million GBP | 40.37% |
| 2021 | 6.98 Million GBP | 48.46% |
| 2020 | 4.7 Million GBP | 18.28% |
| 2019 | 3.97 Million GBP | 7.98% |
| 2018 | 3.68 Million GBP | 53.63% |
| 2017 | 2.39 Million GBP | 13.54% |
| 2016 | 2.11 Million GBP | 40.43% |
| 2015 | 1.5 Million GBP | 32.98% |
| 2014 | 1.13 Million GBP | 75.35% |
| 2013 | 645 Thousand GBP | -12.41% |
| 2012 | 736.41 Thousand GBP | -5.47% |
| 2011 | 779 Thousand GBP | 8.04% |
| 2010 | 721 Thousand GBP | -42.18% |
| 2009 | 1.24 Million GBP | -23.45% |
| 2008 | 1.62 Million GBP | -16.85% |
| 2007 | 1.95 Million GBP | -4.21% |
| 2006 | 2.04 Million GBP | 24.77% |
| 2005 | 1.63 Million GBP | 0.0% |
| 2004 | 1.63 Million GBP | 53.18% |
| 2003 | 1.07 Million GBP | 112.72% |
| 2002 | 503 Thousand GBP | 32.72% |
| 2001 | 379 Thousand GBP | 6.16% |
| 2000 | 357 Thousand GBP | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 8.47 Million GBP | 0.0% |
| 2024 Q1 | 8.47 Million GBP | 2.81% |
| 2023 Q1 | 8.09 Million GBP | -17.43% |
| 2023 FY | 8.24 Million GBP | -15.92% |
| 2023 Q3 | 8.24 Million GBP | 1.83% |
| 2023 Q4 | 8.24 Million GBP | 0.0% |
| 2023 Q2 | 8.09 Million GBP | 0.0% |
| 2022 Q3 | 9.8 Million GBP | -1.23% |
| 2022 Q2 | 9.92 Million GBP | 0.0% |
| 2022 Q1 | 9.92 Million GBP | 42.12% |
| 2022 FY | 9.8 Million GBP | 40.37% |
| 2022 Q4 | 9.8 Million GBP | 0.0% |
| 2021 Q2 | 7.28 Million GBP | 0.0% |
| 2021 Q4 | 6.98 Million GBP | 0.0% |
| 2021 FY | 6.98 Million GBP | 48.46% |
| 2021 Q1 | 7.28 Million GBP | 54.73% |
| 2021 Q3 | 6.98 Million GBP | -4.05% |
| 2020 Q2 | 3.74 Million GBP | 0.0% |
| 2020 Q4 | 4.7 Million GBP | 0.0% |
| 2020 Q3 | 4.7 Million GBP | 25.67% |
| 2020 FY | 4.7 Million GBP | 18.28% |
| 2020 Q1 | 3.74 Million GBP | 0.0% |
| 2019 Q3 | 3.58 Million GBP | 112.89% |
| 2019 Q1 | 3.68 Million GBP | 0.0% |
| 2019 FY | 3.97 Million GBP | 7.98% |
| 2019 Q2 | 1.68 Million GBP | -54.29% |
| 2018 Q1 | 2.39 Million GBP | 0.0% |
| 2018 Q3 | 1.68 Million GBP | 0.0% |
| 2018 FY | 3.68 Million GBP | 53.63% |
| 2018 Q4 | 3.68 Million GBP | 118.76% |
| 2017 Q4 | 2.39 Million GBP | 47.93% |
| 2017 Q3 | 1.62 Million GBP | 0.0% |
| 2017 Q2 | 1.62 Million GBP | -23.25% |
| 2017 Q1 | 2.11 Million GBP | 0.0% |
| 2017 FY | 2.39 Million GBP | 13.54% |
| 2016 Q2 | 1.25 Million GBP | -16.49% |
| 2016 Q1 | 1.5 Million GBP | 0.0% |
| 2016 Q3 | 1.25 Million GBP | 0.0% |
| 2016 Q4 | 2.11 Million GBP | 68.15% |
| 2016 FY | 2.11 Million GBP | 40.43% |
| 2015 FY | 1.5 Million GBP | 32.98% |
| 2015 Q2 | 749 Thousand GBP | -33.78% |
| 2015 Q3 | 749 Thousand GBP | 0.0% |
| 2015 Q4 | 1.5 Million GBP | 100.8% |
| 2015 Q1 | 1.13 Million GBP | 0.0% |
| 2014 Q3 | 822 Thousand GBP | 0.0% |
| 2014 Q4 | 1.13 Million GBP | 37.59% |
| 2014 FY | 1.13 Million GBP | 75.35% |
| 2014 Q2 | 822 Thousand GBP | 27.44% |
| 2014 Q1 | 645 Thousand GBP | 0.0% |
| 2013 FY | 645 Thousand GBP | -12.41% |
| 2013 Q2 | 745 Thousand GBP | 1.17% |
| 2013 Q3 | 745 Thousand GBP | 0.0% |
| 2013 Q4 | 645 Thousand GBP | -13.42% |
| 2013 Q1 | 736.41 Thousand GBP | 0.06% |
| 2012 FY | 736.41 Thousand GBP | -5.47% |
| 2012 Q4 | 736 Thousand GBP | 7.16% |
| 2012 Q3 | 686.84 Thousand GBP | 0.0% |
| 2012 Q2 | 686.84 Thousand GBP | -11.83% |
| 2012 Q1 | 779 Thousand GBP | 0.0% |
| 2011 FY | 779 Thousand GBP | 8.04% |
| 2011 Q3 | 478 Thousand GBP | 0.0% |
| 2011 Q1 | 721 Thousand GBP | 0.0% |
| 2010 Q3 | 1.35 Million GBP | 0.0% |
| 2010 FY | 721 Thousand GBP | -42.18% |
| 2010 Q1 | 1.24 Million GBP | 0.0% |
| 2009 Q3 | 1.2 Million GBP | 0.0% |
| 2009 Q1 | 1.62 Million GBP | 0.0% |
| 2009 FY | 1.24 Million GBP | -23.45% |
| 2008 FY | 1.62 Million GBP | -16.85% |
| 2008 Q3 | 1.78 Million GBP | 0.0% |
| 2008 Q1 | 1.96 Million GBP | 0.0% |
| 2007 FY | 1.95 Million GBP | -4.21% |
| 2007 Q3 | 1.67 Million GBP | 0.0% |
| 2007 Q1 | 2.04 Million GBP | 0.0% |
| 2006 Q1 | 1.63 Million GBP | 0.0% |
| 2006 FY | 2.04 Million GBP | 24.77% |
| 2006 Q3 | 1.07 Million GBP | 0.0% |
| 2005 Q1 | 740 Thousand GBP | 0.0% |
| 2005 FY | 1.63 Million GBP | 0.0% |
| 2005 Q3 | 1.09 Million GBP | 0.0% |
| 2004 Q3 | 712 Thousand GBP | 0.0% |
| 2004 Q1 | 1.07 Million GBP | 0.0% |
| 2004 FY | 1.63 Million GBP | 53.18% |
| 2003 FY | 1.07 Million GBP | 112.72% |
| 2003 Q3 | 599 Thousand GBP | 0.0% |
| 2002 FY | 503 Thousand GBP | 32.72% |
| 2001 FY | 379 Thousand GBP | 6.16% |
| 2000 FY | 357 Thousand GBP | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -128.492% |
| Arrayit Corporation | 7.49 Million USD | -9.97% |
| Atlantic International Corp. | 3.82 Million USD | -115.326% |
| Biocept, Inc. | 22.01 Million USD | 62.549% |
| Bioqual, Inc. | 18.93 Million USD | 56.468% |
| CardioGenics Holdings Inc | 1.79 Million USD | -359.295% |
| DermTech, Inc. | 64.75 Million USD | 87.269% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 98.878% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 33.441% |
| iMD Companies, Inc. | 1.67 Million USD | -392.41% |
| IDenta Corp. | 1.01 Million USD | -713.693% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 70.721% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -2666.935% |
| InVitro International | 78.99 Thousand USD | -10336.764% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 58.214% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -6276.018% |
| Medical Imaging Corp. | 9.51 Million USD | 13.377% |
| NovelStem International Corp. | 4.2 Million USD | -96.002% |
| Optigenex Inc. | 9.57 Million USD | 13.861% |
| PharmChem, Inc. | 558.64 Thousand USD | -1375.708% |
| Proteome Sciences plc | 18.48 Million USD | 55.411% |
| Response Genetics, Inc | 15.86 Million USD | 48.043% |
| Rennova Health, Inc. | 49.66 Million USD | 83.402% |
| RushNet, Inc. | 6.23 Million USD | -32.137% |
| ScreenPro Security Inc. | 1.6 Million USD | -415.061% |
| Stella Diagnostics Inc. | 18 Million USD | 54.214% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | -0.488% |
| Todos Medical Ltd. | 50.15 Million USD | 83.564% |